Watch a video by prof. Banach, who gives an overview of the key messages in the new Polish lipid guidelines.
AHA 2021 Alexander Blood talks about the design of a remote algorithm-based program for hypertension and lipid management and shares the outcomes of the first 10,000 patients enrolled in this program.
AHA 2021 Prof. Ferdinand summarizes and discusses the results from the Chinese Rural Hypertension Control (CRHC) Project.
Jackie Bosch presents the results of the HOPE-3 study that show that CV benefits of statin treatment continued for at least three more years after stopping medication in individuals at intermediate risk for CV events.
Although relative risk for MI per 1 mmol/L higher LDL-c is similar across age groups, absolute risk for MI and ASCVD per LDL categories is much higher in individuals 80-100 years compared to those <70 years.
AHA 2020 Prof. Francis presents and interprets the findings of the SAMSON trial, in which symptom burden during statin, placebo and tablet-free periods was examined in patients who previously discontinued statins.
A diagnostic model with data from the Lifelines cohort study improved early detection of unrecognized AF, HF and CAD in primary care. This translated into the development of a patient questionnaire.
Diabetes summit Prof. Lehmann considers factors that may play a role when diabetes guidelines are not adequately implemented, and how these barriers may be overcome.
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.